Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
Health Technology Assessment (Winchester, England)
|
April 15, 2008
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
Y-F Chen, P Jobanputra, P Barton, et al.
Scandinavian Journal of Immunology
|
February 1, 1997
CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro
F R Brennan, K Mikecz, T T Glant, et al.
Health Technology Assessment (Winchester, England)
|
October 20, 2006
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Y-F Chen, P Jobanputra, P Barton, et al.
Annals of the Rheumatic Diseases
|
August 1, 1992
Cellular immunity to cartilage proteoglycans: relevance to the pathogenesis of ankylosing spondylitis
P Jobanputra, E H Choy, G H Kingsley, et al.
Arthritis and Rheumatism
|
August 1, 1996
Modulation of human chondrocyte integrins by inflammatory synovial fluid
P Jobanputra, H Lin, K Jenkins, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|
January 8, 1998
Hyperpolarisation of cultured human chondrocytes following cyclical pressure-induced strain: evidence of a role for alpha 5 beta 1 integrin as a chondrocyte mechanoreceptor
M O Wright, K Nishida, C Bavington, et al.
Health Technology Assessment (Winchester, England)
|
March 29, 2011
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
K Malottki, P Barton, A Tsourapas, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
Health Technology Assessment (Winchester, England)
|
April 15, 2008
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
Y-F Chen, P Jobanputra, P Barton, et al.
Scandinavian Journal of Immunology
|
February 1, 1997
CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro
F R Brennan, K Mikecz, T T Glant, et al.
Health Technology Assessment (Winchester, England)
|
October 20, 2006
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Y-F Chen, P Jobanputra, P Barton, et al.
Annals of the Rheumatic Diseases
|
August 1, 1992
Cellular immunity to cartilage proteoglycans: relevance to the pathogenesis of ankylosing spondylitis
P Jobanputra, E H Choy, G H Kingsley, et al.
Arthritis and Rheumatism
|
August 1, 1996
Modulation of human chondrocyte integrins by inflammatory synovial fluid
P Jobanputra, H Lin, K Jenkins, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|
January 8, 1998
Hyperpolarisation of cultured human chondrocytes following cyclical pressure-induced strain: evidence of a role for alpha 5 beta 1 integrin as a chondrocyte mechanoreceptor
M O Wright, K Nishida, C Bavington, et al.
Health Technology Assessment (Winchester, England)
|
March 29, 2011
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
K Malottki, P Barton, A Tsourapas, et al.
Page
of 5